EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link: https://ebookbell.com/faq

We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.

For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Combination Cancer Therapy Modulators And Potentiators Cancer Drug Discovery And Development 1st Edition Gary K Schwartz

SKU: BELL-2530600

$ 31.00 ~~$ 45.00~~ (-31%)

0 reviews

Combination Cancer Therapy Modulators And Potentiators Cancer Drug Discovery And Development 1st Edition Gary K Schwartz instant download after payment.

Publisher: Humana Press

File Extension: PDF

File size: 2.37 MB

Pages: 294

Author: Gary K. Schwartz

ISBN: 1588292002

Language: English

Year: 2004

Edition: 1

Product desciption

Combination Cancer Therapy Modulators And Potentiators Cancer Drug Discovery And Development 1st Edition Gary K Schwartz by Gary K. Schwartz 1588292002 instant download after payment.

Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.